Tolero Pharmaceuticals to Present at the International Conference on Leukemia and Hematologic Oncology in Rome, Italy
SALT LAKE CITY, UT - October 11, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematological diseases, announced today that David J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present the keynote address at the International Conference on Leukemia and Hematologic Oncology, which is being held from October 17-18, 2016 in Rome, Italy. The address titled "Sequential Treatment of AML patients with Alvocidib followed by Cytarabine and Mitoxantrone is highly effective through a mechanism dependent on MCL-1 expression and functions" will take place on October 17, 2016 at 10:00 AM CET.
Steve Warner, Ph.D., Vice President, Drug Discovery and Development, will also present as part of a special session titled "Inhibition of AXL kinase reverses the mesenchymal phenotype in leukemia cells through the disruption of retinoic acid signaling" on October 18, 2016 at 11:20 AM CET.
Alvocidib is a potent small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) in development as a combination therapy for frontline and relapsed/refractory AML. CDK9 is a protein critical to the regulation of gene expression including the MCL-1 gene and other important genes involved in cancer. Given the key role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 is an attractive target for the treatment of various cancers.
About TP-0903 and AXL Kinase Inhibitors
TP-0903 is a small molecule inhibitor of AXL kinase. AXL, along with other members of the TAM family of kinases, are key regulators of the mesenchymal phenotype of cancer cells. Mesenchymal cancer cells have increased invasion and migratory properties, enhanced cell survival characteristics in stressed environments, and critically, increased resistance to both targeted and traditional chemotherapies. Consequently, targeting AXL kinase with TP-0903 is an attractive way to overcome resistance to chemotherapy by targeting mesenchymal cancer cell populations.
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with cancer and blood diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.
Tolero Pharmaceuticals, Inc.
Click here to open a PDF version